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Background    To date, there has been no practical guidelines for the prescription of antiepileptic 
drugs (AEDs) in brain tumor patients in Korea. Thus, the Korean Society for Neuro-Oncology (KSNO), 
a multidisciplinary academic society, had begun preparing guidelines for AED usage in brain tumors 
since 2019.
Methods    The Working Group was composed of 27 multidisciplinary medical experts in Korea. 
References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CEN-
TRAL using specific and sensitive keywords as well as combinations of the keywords.
Results    The core contents are as follows. Prophylactic AED administration is not recom-
mended in newly diagnosed brain tumor patients without previous seizure history. When AEDs are ad-
ministered during peri/postoperative period, it may be tapered off according to the following recom-
mendations. In seizure-naïve patients with no postoperative seizure, it is recommended to stop or 
reduce AED 1 week after surgery. In seizure-naïve patients with one early postoperative seizure (<1 week 
after surgery), it is advisable to maintain AED for at least 3 months before tapering. In seizure-naïve pa-
tients with ≥2 postoperative seizures or in patients with preoperative seizure history, it is recommended 
to maintain AEDs for more than 1 year. The possibility of drug interactions should be considered when 
selecting AEDs in brain tumor patients. Driving can be allowed in brain tumor patients when proven to 
be seizure-free for more than 1 year.
Conclusion    The KSNO suggests prescribing AEDs in patients with brain tumor based on the cur-
rent guideline. This guideline will contribute to spreading evidence-based prescription of AEDs in brain 
tumor patients in Korea. 
Key Words  Korean Society for Neuro-Oncology; Guideline; Brain tumors; Antiepileptic drug; 
Practice.
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INTRODUCTION
Seizure is one of the most common medical complications 
in brain tumor patients [1,2]. Up to two third of patients di-
agnosed with a brain tumor will experience at least 1 seizure 
throughout their disease course [3]. Antiepileptic drugs (AEDs) 
are frequently prescribed in brain tumor patients for therapeu-
tic or prophylactic purposes [4]. Seizures can be provoked dur-
ing the perioperative period of brain tumor resection and it is 
widely accepted that perioperative seizures must be controlled 
with AEDs [5], however the adequate duration of AED main-
tenance is not established [6]. Moreover, clinicians are still con-
troversial about the use of prophylactic AEDs for brain tumor 
surgery in patients with no prior seizure history [7]. 
Recently, a web-based survey was conducted on the admin-
istration of AEDs in patients with brain tumors among the Ko-
rean Society for Neuro-Oncology (KSNO) members [8]. The 
majority of respondents (95.2%) routinely prescribed AEDs 
during peri/postoperative period for patients with previous 
seizure history. Also, 72.8% of respondents routinely prescribed 
AEDs for seizure-naïve patients. The duration of prophylac-
tic AED administration was widely variable according to the 
history of epilepsy and the location of tumor. Levetiracetam 
(82.9%) was the most preferred AED for seizure prophylaxis 
in brain tumor patients in Korea.
To date, a practical guideline for AED prescription in brain 
tumor patients is not available in Korea. Therefore, the KSNO, 
a multidisciplinary academic society for central nervous system 
(CNS) tumors in Korea, established a new Guideline Working 
Group chapter to discuss guidelines on the prescription of AEDs 
in brain tumor patients. The objective of this guideline is to pro-
vide physicians with evidence-based recommendations and 
consensus expert opinion for prescribing AEDs in patients with 
brain tumor. It will also provide a source of knowledge for in-
stitutions and insurance companies involved in the manage-
ment of brain tumor in Korea.
KSNO GUIDELINE WORKING GROUP
A new chapter of Working Group was appointed by the 
KSNO in 2019 to develop a clinical guideline for management 
of patients with brain tumor. These guidelines should be opti-
mized considering the unique medical circumstance in Korea. 
The KSNO Guideline Working Group was composed of 27 
medical experts in Korea, including 15 neurosurgeons, 6 ra-
diation oncologists, 1 medical oncologist, 2 neuroradiologists, 
2 pathologists, and 1 neurologist.
References were searched from PubMed, MEDLINE, EM-
BASE, and Cochrane CENTRAL using specific and sensitive 
keywords as well as combinations of keywords. The scope of 
the brain tumors included all histological grades of primary 
and metastatic brain tumors. The purpose of AED prescrip-
tions covered prophylactic use, symptomatic control and with-
drawal strategy. The driving issues regarding seizure control in 
brain tumor patients were evaluated. The final reference list was 
generated based on the originality and relevance to the scope 
of this guideline. 
Scientific evidence was evaluated and graded according to 
the following categories: high level evidence (obtained from 
multiple populations and derived from randomized clinical 
trials or meta-analysis or systemic review), and low level evi-
dence (obtained from limited population and derived from 
non-randomized studies, including observational studies, co-
hort studies, and case-control studies).
To establish the recommendation levels, the following cri-
teria were used. Level I (strong recommendation) required a 
high level evidence and uniform agreement among panels. Level 
II (weak recommendation) required a high level evidence but 
not uniform agreement among panels or low level evidence 
but uniform agreement among panels. Level III (no consensus; 
individual decision) required a low level evidence but not uni-
form agreement among panels. Level IV (not recommended) 
required contents being not beneficial or harmful.
 
PROPHYLACTIC ANTIEPILEPTIC DRUG 
PRESCRIPTION
Preventive anticonvulsant administration is not rec-
ommended in patients with newly diagnosed brain 
tumors who do not have a history of seizure (Level I) 
(Table 1, Fig. 1)
The high risk for development of seizures and epilepsies in 
brain tumor raised the question of prophylactic AED treatment 
in patients with newly diagnosed brain tumor. While initiation 
of AEDs is justified after a first seizure in patients with brain 
tumors, prophylactic AED should not be used in seizure naïve 
brain tumor patients [9]. In 2000, the American Academy of 
Neurology (AAN) recommended against prophylactic AED 
prescription for patients with brain tumor [10]. Afterward, sev-
eral randomized controlled studies [11-13] and meta-analyses 
[14,15] have confirmed that prophylactic AED is not benefi-
cial for preventing first seizure in brain tumor patients.
However, prophylactic AEDs may be considered in the pres-
ence of the following high-risk factors: 1) low-grade gliomas, 
2) tumors invading cortical area of the brain, 3) multifocal tu-
mors, and 4) tumors located in the temporal lobe or in insular 
region [5]. These factors should be considered when deciding 
whether to prescribe prophylactic AEDs to each patient. 
Low-grade gliomas that are frequently associated with sei-
zure are recently categorized as low-grade developmental and 
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in the peri/postoperative period. Only two (4.4%) respondents 
never prescribed prophylactic AEDs in this situation [8]. This 
is in line with the survey studies performed in thousands of 
neurosurgeons about their real clinical practice, that 63–70% 
of neurosurgeons routinely prescribed AEDs postoperatively 
to patients without seizure history [11-13].
Even when prophylactic AEDs were prescribed to brain tu-
mor patients who have not had seizure, AAN recommends ta-
pering and discontinuing AEDs after the first postoperative 
week [10]. No subsequent studies have provided evidence 
against this recommendation.  
In seizure-naïve brain tumor patients when seizure occurred 
once during acute postoperative period (<1 week after sur-
gery), it is advisable to maintain AED and if no additional 
seizures occur afterward then to stop or reduce AEDs 3 
months after surgery (Level III) (Table 1, Fig. 1)
Early postoperative seizures are rare after supratentorial neu-
rosurgery [25]. It has been demonstrated that only rare por-
tion of patients (about 1%) experience seizure within 24 hours 
after brain tumor surgery [25], and it is unlikely that early post-
operative seizure to be caused by postoperative hematoma or 
metabolic abnormality [26]. Moreover, a large proportion of 
patients who experienced early postoperative seizure after su-
pratentorial neurosurgery also had preoperative seizures. There-
fore, seizure will rarely occur during the early postoperative pe-
riod in seizure naïve patients. However, when it occurs it is 
advisable to maintain AED for longer period than 1 week. 
There is limited consensus on the timing of AED withdrawal 
after brain tumor surgery [9]. No studies had systemically ex-
amined AED withdrawal in tumor-related seizures, therefore, 
epilepsy associated brain tumors (LEATs). LEAT contains gan-
glioglioma, dysembryoplastic neuroepithelial tumor, angio-
centric glioma, isomorphic diffuse glioma and papillary glio-
neuronal tumor which account for more than 70% of epilepsy-
related brain tumors [16]. The incidence of seizure in patients 
with LEAT is estimated to be between 70–90% [17], which is 
substantially higher than in high-grade gliomas (25–60%), me-
ningiomas (25%), or brain metastases (15%) [18-21]. High-
grade tumors have relatively lower rate of seizures [1,22].
The location of the tumor is also important for assessing the 
risk of seizure occurrence. Brain tumors located in the super-
ficial cortical area is much likely to cause seizure than those 
in the noncortical deeper area [1,23,24]. Multiple lesions are 
associated with a higher risk compared to solitary lesions. Brain 
tumors located in temporal lobe and insular regions are asso-
ciated with intractable epilepsy [23,24]. Additionally, frontal 
and parietal tumors are known for higher risk of causing epi-




In seizure-naïve brain tumor patients when seizure did not 
occur after surgery, it is advisable to stop or reduce prophy-
lactic AEDs 1 week after surgery (Level II) (Table 1, Fig. 1)
AED is often prescribed during the peri/postoperative pe-
riod of brain tumor surgery. According to a National Consen-
sus Survey in Korea, more than 70% of respondents (32 of 44, 
72.8%) prescribed prophylactic AEDs for seizure naïve patient 
Table 1. Summary of the Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage in Brain Tumor
Recommendations on AED prescription
Recommendation 
level
•  Preventive anticonvulsant administration is not recommended in patients with newly diagnosed brain tumors who do 
not have a history of seizure
Level I
•  In seizure-naïve brain tumor patients when seizure did not occur after surgery, it is advisable to stop or reduce  
prophylactic AEDs 1 week after surgery
Level II
•  In seizure-naïve brain tumor patients when seizure occurred once during acute postoperative period (<1 week after 
surgery), it is advisable to maintain AED and if no additional seizures occur afterward then to stop or reduce AEDs  
3 months after surgery
Level III
•  In seizure-naïve brain tumor patients when seizure occurred more than twice after surgery, AEDs should be maintained 
and if the patient remains seizure-free for over 1 year, stopping or reducing AEDs can be considered
Level III
• In patients with brain tumors who had preoperative epilepsy (or seizures), AED should be maintained for at least a year 
after surgery
Level II
• Drug interactions should be considered when selecting AEDs in patients with brain tumors Level II
•  Even in brain tumor patients who previously experienced seizures, when seizure-free period with or without AEDs is 
longer than 1 year, driving can be allowed. However, it is not allowed to drive during the tapering period of AEDs
Level III
AED, antiepileptic drug
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the decision has to be made based on what is known in general 
[27]. In patients with single seizure during the acute postop-
erative period (<1 week after surgery), AED can be gradually 
withdrawn from 3 months after surgery. 
In seizure-naïve brain tumor patients when seizure occurred 
more than twice after surgery, AEDs should be maintained 
and if the patient remains seizure-free for over 1 year, stop-
ping or reducing AEDs can be considered (Level III) 
(Table 1, Fig. 1)
If seizure occurred more than twice after surgery, it is more 
likely that the patient had subtle seizures from preoperative 
stage [28]. Therefore, in these conditions, AEDs should be 
maintained for longer period. 
When the patient remains seizure-free for at least 1 year, AED 
reduction or discontinuation can be considered. A patient can 
be considered ‘seizure-free’ when the period without seizures 
has elapsed equal to three times the longest inter-seizure inter-
val over the previous year [29].
In patients with brain tumors who had preoperative epi-
lepsy (or seizures), AED should be maintained for at least 
a year after surgery (Level II) (Table 1, Fig. 1)
In patients with history of preoperative seizure or epilepsy, 
AED reduction or discontinuation should be determined in 
the same way as in other epilepsy. In these conditions, AED 
withdrawal may be carefully attempted after a sufficient amount 
of seizure-free period, according to the clinician’s judgment con-
sidering various clinical factors. 
AED can be withdrawn after a minimum of 1 year of seizure 
freedom when the seizure history of the patient is shorter than 
6 months and tumors are completely removed after surgery 
(Level III) (Fig. 1). The percentage of achieving seizure freedom 
after brain tumor surgery is highly variable, affected by the type 
of tumors, residual tumors, duration of uncontrolled epilepsy, 
and others [9]. More than 50% of brain tumor can reach sei-
zure-freedom after brain surgery so withdrawal of AED should 
be attempted whenever possible [9]. When tumors are com-
pletely resected and the preoperative seizure duration is short 
it is more likely to achieve seizure-freedom after surgery [30], 
thus AED withdrawal should be actively considered. 
AEDs withdrawal can be attempted after a minimum of 2 
years of seizure freedom in the presence of any of the follow-
ing conditions: 1) patients with a longer seizure history than 
6 months, 2) incomplete tumor resection, 3) epileptiform EEG 
discharges after surgery, 4) preoperative drug-resistant sei-
zures, 5) focal seizure without a loss of consciousness (Level 
III) (Fig. 1). Gross total resection of tumor is the most impor-
tant predictor for seizure freedom in brain tumor patients [1]. 
Therefore, AED withdrawal should be considered carefully 
after longer seizure-free period when residual tumor is pres-
ent. Since no studies systematically examined AED withdrawal 
in brain tumor-related epilepsy, decision has to be made, trans-
ferring what is known in general [5,9]. In the general epilepsy 
population, long duration of active seizure, epileptiform dis-
charges on EEG, multiple AEDs required for seizure control, 
and focal seizure without a loss of consciousness are consid-
ered poor prognostic factor for successful withdrawal of AEDs 
[31-33]. 












Fig. 1. Guideline for AED maintenance and withdrawal in brain tumor patients. Sz, seizure; Hx, history; PostOp, postoperative; EEG, elec-
troencephalogram; PreOp, preoperative; LOC, loss of consciousness; AED, antiepileptic drug.
No Sz
1 early-PostOp Sz
≥ 2 PostOp Sz
•  Sz Hx ≤6 mo &  
complete tumor resection
•  Sz Hx >6 mo; or
•  Incomplete tumor  
resection; or
•  EEG epileptiform  
discharges; or
•  PreOp intractable Sz; or
•  Focal Sz without LOC
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may cause psychiatric adverse events, such as aggressive be-
havior, agitation, psychosis [44] that can interfere with manage-
ment of brain tumor patients. Otherwise, lacosamide are less 
likely to cause cognitive and psychiatric side effects [45]. 
DRIVING
Even in brain tumor patients who previously experi-
enced seizures, when seizure-free period with or with-
out AEDs is longer than 1 year, driving can be allowed. 
However, it is not allowed to drive during the tapering 
period of AEDs (Level III) (Table 1)
Some countries provide detailed recommendations on the 
driving of brain tumor patients [46]. However, in general, it is 
similar to recommendations in patients with epilepsy due to 
other causes. In United Kingdom, government recommends 
patients not to drive for 6–12 months and 1–2 years after cra-
niotomy of benign and malignant brain tumors, respectively. 
More strict restrictions are applied to professional drivers [47]. 
In United States, the prerequisites for allowing epilepsy patients 
to drive vary from state to state, and specific recommendations 
for brain tumor patients are not available. According to a sur-
vey study, US clinicians tended to restrict driving for longer 
postoperative period in patients with high-grade brain tumors 
or in professional drivers [48].
To date, there are no official recommendations on the driv-
ing of brain tumor patients in Korea. Thus, it is reasonable to 
apply the same recommendation on driving suggested in other 
epilepsy patients. The Korean Epilepsy Society limits epilepsy 
patients from driving until they are proven seizure-free for more 
than 1 year [49]. In particular, newly-diagnosed epilepsy pa-
tients or patients who underwent reduction or withdrawal of 
AEDs should not be permitted to drive until remaining seizure-
free for more than 1 year. However, driving is allowed for pa-
tients who have proven to have only focal seizure that does not 
cause alteration of consciousness (focal aware seizure) [49,50]. 
CONCLUSION
To date, no practical guideline for AED prescription in brain 
tumor patients were available. Thus, KSNO developed the cur-
rent guideline that could be used by physicians under medical 
circumstances in Korea. The KSNO Guideline Working Group 
have previously developed several guidelines regarding the 
management of gliomas. Now, the working group composed 
of 27 multidisciplinary medical experts in Korea prepared “The 
Korean Society for Neuro-Oncology (KSNO) Guideline for 
Antiepileptic Drug Usage of Brain Tumor: Version 2021.1.”
In summary, prophylactic AED administration is not rec-
ommended in newly diagnosed brain tumor patients without 
AED dose should be increased again and maintained longer. It 
is controversial whether to consider AED withdrawal in high-
grade glioma (HGG) patients. Some researchers insist that AED 
withdrawal is not recommended in HGG patient, because of 
the progressive nature of the tumor [34,35]. On the other hand, 
some researchers support AED withdrawal even in HGG when-
ever possible, considering the adverse effect of AEDs and the 
chance of masking tumor progression that can be detected 
by worsening seizures [33]. Therefore, the adjustment of AEDs 
after resection of HGG should be determined case by case 
according to the clinician’s decision. 
ANTIEPILEPTIC DRUG SELECTION
Drug interactions should be considered when select-
ing AEDs in patients with brain tumors (Level II) 
(Table 1)
Cytochrome P450 (CYP) enzyme inducers and inhibitors af-
fect the blood concentration of anticancer drugs, so care must 
be taken during prescription (Level II). Several AEDs dem-
onstrate CYP drug interaction, which may affect the level of 
chemotherapeutic agents. Chemotherapeutic agents often have 
a narrow therapeutic window close to the maximum tolerated 
dose, so these interactions can easily result in insufficient an-
ti-tumor effect or in drug toxicity [36]. Carbamazepine, phe-
nytoin, phenobarbital are CYP enzyme inducers, mainly of 2C9, 
SC19, and 3A4 [37], which may lower the serum level of che-
motherapeutic agents and reduce the anti-tumor effects. On the 
other hand valproate contains CYP enzyme inhibiting proper-
ties so that it may increase the serum level of concomitant che-
motherapeutic agents which will lead to increased toxicity [36].
Levetiracetam, zonisamide, lacosamide, perampanel, and 
pregabalin have minimal drug interactions therefore can be ad-
ministered relatively safely to patients receiving chemotherapy 
(Level III). Most of second and third generation AEDs are not 
enzyme-inducing, so their use is preferred in brain tumor pa-
tients [36]. Several studies investigated the efficacy and toler-
ability of levetiracetam in brain tumor patients. All studies 
reported fairly good efficacy and tolerability [9]. Lacosamide 
[38,39] and perampanel [40,41] are proven to be well tolerated 
and effective on seizure control in brain tumor patients, both 
as monotherapy and add-on therapy. 
Adverse effects of AEDs should also be taken into consider-
ation when prescribing them in brain tumor patients. Adverse 
effects occur more frequently in patients with brain tumor com-
pared with the overall population of people with epilepsy [36, 
42]. Many AEDs may cause cytopenia or rash, topiramate may 
induce cognitive dysfunction, and topiramate or zonisamide 
may cause weight loss, which are critical issues in the manage-
ment of brain tumor patients [43]. Levetiracetam or perampanel 
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previous seizure history. In seizure-naïve patients with no post-
operative seizure, it is advisable to stop or reduce AED 1 week 
after surgery. In seizure-naïve patients with one early postop-
erative seizure (<1 week after surgery), AED should be main-
tained for at least 3 months before tapering. In seizure-naïve 
patients with ≥2 postoperative seizures or in patients with pre-
operative seizure history, AEDs should be maintained for more 
than 1 year. The possibility of drug interactions should be con-
sidered when selecting AEDs. Driving can be allowed to those 
proven to be seizure-free for at least 1 year.
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